|View printer-friendly version|
Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highlighting New Interim Data for Andexanet Alfa
The conference call and live audio webcast will be hosted by Dr.
|ANNEXA-4 Late-Breaking Oral Presentation Details|
|Session:||(409) Late-Breaking Clinical Trials Session: Interventional Cardiology|
|Title:||ANNEXA-4: Interim Report on the ANNEXA-4 Study: Andexanet for Reversal of|
|Anticoagulation in Factor Xa-Associated Acute Major Bleeding|
|Presenter:||Stuart J. Connolly, M.D., Professor Emeritus of Medicine, McMaster University, Hamilton|
|Date:||Monday, March 12, 10:45 a.m. – 11:45 a.m. ET|
|Room:||ACC.18 Main Tent, Hall C|
Webcast and Conference Call Details
To access the live investor webcast and presentation slides on Monday, March 12 at 12:30 p.m. ET (9:30 a.m. PT), go to the Investor Relations section of the company's website at http://investors.portola.com. A replay of the webcast will be available for 30 days. For participants that wish to participate in the Q&A portion, a live conference call can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 8493604. Please note you will also need to open the webcast in order to view the accompanying presentation slides. Analysts and investors who would like to attend the event in Orlando should RSVP to Cara Miller at firstname.lastname@example.org for additional details.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company's first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.